Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение волосатоклеточного лейкоза

Литература

  1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-630
  2. Went PT, Zimpfer A, Pehrs A, et al. High specificity of combined TRAP and DBA.44 expression for hairy cell leukaemia. American Journal of Surgical Pathology. 2005;29:474-478
  3. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363:1869-1870
  4. Foucar K, Falini B, Catovsky D, Stein H. Hairy cell leukaemia. In: WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. (ed. by Swerdlow SH, Campo E, Harris NL, et al.), pp. 188– 190. IARC Press, Lyon. 2008
  5. Miranda RN, Briggs RC, Kinney MC, et al. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukaemia. Modern Pathology. 2000;13:1308-1314
  6. Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. American Journal of Clinical Pathology. 2006;125:251-259Del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303–308
  7. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy cell leukemia. New England Journal of Medicine. 2011;364:2305–2315
  8. Else M, Dearden CE, Matutes E, et al. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology. 2009;145:733-740
  9. Mercieca J, Puga M, Matutes E, et al. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leukaemia and Lymphoma. 1994;14(Suppl. 1):79–83
  10. Mercieca J, Matutes E, Emmett E, et al. 2-chlordeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. British Journal of Haematology. 1996;93:409–411
  11. Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009;2(2):111-120
  12. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia in patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45–51
  13. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leukaemia and Lymphoma. 2011;52(Suppl. 2):21–24
  14. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of the front-line treatment of hairy cell leukemia with 2- cholordeoxyadenosine. Haematologica. 2004;89:309–313
  15. Zinzani PL, Pellegrini C, Stefoni V, et al. (2010) Hairy cell leukaemia: evaluation of the longterm outcome in 121 patients. Cancer. 2010;116:4788–4792
  16. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology. 2004;73:412–417
  17. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2- chlorodeoxyadenosine for symptomatic hairy cell leukaemia. Journal of Clinical Oncology. 1995;13:989-995
  18. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versusdaily schedule for untreated hairy cell leukemia: final report from the Polish Adult Leukaemia Group (PALG) of a prospective, randomised, multicenter trial. Blood. 2007;109:3672–3675
  19. Zenhausern R, Leupin N, Hsu Schmitz SF, et al. A randomized study of daily versus weekly administration of 2 chlorodeoxyadenosine in patients with hairy cell leukemia. Blood. 2007;110:1352a
  20. Chadha P, Rademaker AW, Mendiratta P, et al. (2005) Treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–246
  21. Liliemark J, Albertioni F, Hassan M, Juliusson G. (1998) On the bioavailablity of oral and subcutaneous 2-chloro-2’-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology. 1998;10:1514–1518
  22. Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. British Journal of Haematology. 2011;152:35–51
  23. Pileri S, Sabattini E, Poggi S, et al. Bone marrow biopsy in hairy cell leukaemia (HCL) patients, histological and immunohistological analysis of 46 cases treated with different therapies. Leukemia and Lymphoma. 1994;14(Suppl.1):67–71
  24. Konwalinka G, Schirmer M, Hilbe W, et al. Minimal residual disease in hairy cell leukaemia after treatment with 2 chlorodeoxyadenosine. Blood Cells Molecules and Diseases. 1995;21:142–151
  25. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia extended follow-up. British Journal of Haematology. 2008;143:296–298
  26. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent. refractory hairy cell leukaemia. Cancer. 2007;110:2240–2247
  27. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukaemia. Blood. 2006;107:4658–4662
  28. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukaemia after a single course of cladribine. Blood. 2010;115,1893–1896
  29. Аль-Ради Л.С., Пивник А.В., Зингерман Б.В., Кравченко С.К. Лечение рецидивов волосатоклеточного лейкоза. Терапевтический архив. 2012;84(7):4-9
  30. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine; an effective combination treatment for hairy cell leukaemia after disease recurrence. Leukemia and Lymphoma. 2011;52(Suppl. 2),75–78
  31. Grever MR. How I treat hairy cell leukaemia. Blood. 2010;115:21–28
  32. Thomas DA, O’Brien S, Bueso-Ramos C, et al. (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906– 3911
  33. Nieva J, Bethel K, Saven, L. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood.2003;102:810– 813
  34. Dearden C, Catovsky D. (1990) Treatment of hairy cell leukaemia with 2- deoxycoformycin. Leukemia and Lymphoma. 1990;1:179–185
  35. Catovsky D. Clinical experience with 2-deoxycoformycin. Hematology and Cell Therapy. 1996;38:S103–S107
  36. Summers T, Jaffe E. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leukemia and Lymphoma. 2011;52(Suppl. 2), 6-10
  37. Robak T. Management of hairy cell leukemia variant. Leukemia and Lymphoma. 2011;52(Suppl. 2), 53-56
  38. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunophenotyping. Leukemia and Lymphoma. 2011;52(Suppl. 2), 65-68
  39. Tiacci E., Trifonov V., Schiavoni G. et al. BRAF Mutations in Hairy-Cell Leukemia. N Engl J Med 2011;364:2305-15
  40. Dietrich S., Glimm H., Andrulis M. et al. BRAF Inhibition in Refractory Hairy-Cell Leukemia N Engl J Med 2012 366;21
  41. Урнова Е.С., Аль-Ради Л.С., Кузьмина Л.А., Карякина А.А., Ковригина А.М., Двирнык В.Н., Якутик И.А., Судариков А.Б., Паровичникова Е.Н., Савченко В.Г. Успешное применение вемурафениба у больного с резистентной формой волосатоклеточного лейкоза. Терапевтический архив, 2013, №7, с.76-78.
  42. Sari E., Nagy ZG., Baghy K., et al. Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt. Pathol Oncol Res. 2014 May

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*